secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0001213900-24-113158
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma reports FY 2024 net loss of $39.4M; FDA approval of LYMPHIR highlights
--------------------------------------------------------------------------------

- Net loss $39.4M ($5.97/share) for FY ended Sep 30, 2024 vs $32.5M ($5.57) prior year.
- Cash & equivalents $3.3M; plans to raise additional capital.
- R&D expense $11.9M, G&A $18.2M; stock-based compensation $11.8M.
- FDA approved LYMPHIR (denileukin diftitox-cxdl) for CTCL; commercial launch expected H1 2025.
- Completed Citius Oncology spin-off (CTOR) on Nasdaq in August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/0001213900-24-113158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/ea0226161-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-113158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer